RLMD RELMADA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1553643 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY59.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-64.7%
ROA-59.7%
ROIC (approx.)-54.7%
Asset turnover—
Leverage & solvency
Liabilities / assets5.6%
Debt / equity0.00x
Current ratio26.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $9.22M | $8.39M | $8.09M | $8.07M | $4.04M | $2.82M | $11.95M | $11.00M |
| SG&A expense | $3.88M | $6.62M | $11.37M | $12.26M | $6.29M | $7.40M | $6.27M | $8.08M |
| Operating income | -$13.10M | -$15.01M | -$19.46M | -$20.33M | -$10.33M | -$10.22M | -$18.22M | -$19.08M |
| Net income | -$13.86M | -$12.91M | -$19.05M | -$19.87M | -$10.09M | -$9.87M | -$17.56M | -$18.66M |
| EPS (basic) | -0.12 | -0.11 | -0.22 | — | -0.30 | -0.30 | -0.58 | — |
| EPS (diluted) | -0.12 | -0.11 | -0.22 | — | -0.30 | -0.30 | -0.58 | — |
| Weighted avg. shares (diluted) | 112.44M | 112.38M | 86.60M | — | 33.19M | 33.19M | 30.41M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.72M | $11.33M | $9.78M | $3.50M | $1.38M | $1.35M | $1.15M | $3.86M |
| Short-term investments | $196.40M | $206.40M | $224.19M | $89.51M | $12.50M | $19.27M | $25.91M | $41.05M |
| Current assets | $205.05M | $219.04M | $235.34M | $93.98M | $14.85M | $21.09M | $27.66M | $45.80M |
| Total assets | $205.30M | $219.06M | $235.36M | $94.00M | $14.88M | $21.12M | $27.68M | $45.82M |
| Current liabilities | $7.78M | $7.42M | $12.89M | $6.43M | $5.19M | $5.13M | $5.23M | $10.29M |
| Total liabilities | $11.56M | $12.50M | $16.63M | $7.49M | $5.41M | $5.17M | $5.24M | $10.30M |
| Shareholders' equity | $193.74M | $206.56M | $218.73M | $86.51M | $9.47M | $15.95M | $22.44M | $35.52M |
| Shares outstanding | 106.69M | 106.67M | 104.89M | 73.33M | 33.19M | 33.19M | 33.19M | 30.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.59M | -$9.61M | -$15.07M | -$14.60M | -$6.72M | -$6.40M | -$18.07M | -$8.80M |
| Investing cash flow | $6.95M | $17.59M | -$135.23M | -$76.93M | $6.75M | $6.68M | $15.36M | $11.35M |
| Financing cash flow | $17,750 | -$6.42M | $156.57M | $93.64M | $0 | — | — | -$172,487 |
| Stock-based compensation | $1.02M | $902,900 | $956,186 | $3.28M | $3.61M | $3.45M | $3.57M | $6.73M |
| Share buybacks | $0 | $6.46M | $3.36M | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.